{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:09:43Z","timestamp":1782551383045,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"DOI":"10.7759\/cureus.61751","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T23:17:15Z","timestamp":1717629435000},"source":"Crossref","is-referenced-by-count":1,"title":["Advancements in Targeted Therapies for the Management of Crohn\u2019s Disease: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Peter","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanisha","family":"LNU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade L","family":"Gambill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atika","family":"Shahzadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase H","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021, 56:489-526. 10.1007\/s00535-021-01784-1","journal-title":"J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.034","article-title":"Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort","volume":"160","author":"Gettler K","year":"2021","unstructured":"Gettler K, Levantovsky R, Moscati A, et al.. Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort. Gastroenterology. 2021, 160:1546-57. 10.1053\/j.gastro.2020.12.034","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2019.1635384","article-title":"New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD","volume":"16","author":"Larabi A","year":"2020","unstructured":"Larabi A, Barnich N, Nguyen HT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020, 16:38-51. 10.1080\/15548627.2019.1635384","journal-title":"Autophagy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104892","article-title":"Genetics and epigenetics of IBD","volume":"159","author":"Annese V","year":"2020","unstructured":"Annese V. Genetics and epigenetics of IBD. Pharmacol Res. 2020, 159:104892. 10.1016\/j.phrs.2020.104892","journal-title":"Pharmacol Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing","volume":"72","author":"Neurath MF","year":"2023","unstructured":"Neurath MF, Vieth M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut. 2023, 72:2164-83. 10.1136\/gutjnl-2023-329964","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn's disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai PS","year":"2019","unstructured":"Dulai PS, Singh S, Vande Casteele N, et al.. Should we divide Crohn's disease into ileum-dominant and isolated colonic diseases?. Clin Gastroenterol Hepatol. 2019, 17:2634-43. 10.1016\/j.cgh.2019.04.040","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy121","article-title":"Upper gastrointestinal tract involvement in Crohn's disease: frequency, risk factors, and disease course","volume":"12","author":"Greuter T","year":"2018","unstructured":"Greuter T, Piller A, Fournier N, et al.. Upper gastrointestinal tract involvement in Crohn's disease: frequency, risk factors, and disease course. J Crohns Colitis. 2018, 12:1399-409. 10.1093\/ecco-jcc\/jjy121","journal-title":"J Crohns Colitis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/genes13122388","article-title":"Genetic and epigenetic etiology of inflammatory bowel disease: an update","volume":"13","author":"Jarmakiewicz-Czaja S","year":"2022","unstructured":"Jarmakiewicz-Czaja S, Zieli\u0144ska M, Sokal A, Filip R. Genetic and epigenetic etiology of inflammatory bowel disease: an update. Genes (Basel). 2022, 13:10.3390\/genes13122388","journal-title":"Genes (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45510","article-title":"Biofilm's impact on inflammatory bowel diseases","volume":"15","author":"Palandurkar GS","year":"2023","unstructured":"Palandurkar GS, Kumar S. Biofilm's impact on inflammatory bowel diseases. Cureus. 2023, 15:e45510. 10.7759\/cureus.45510","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8133-2","article-title":"Crohn's disease: an immune deficiency state","volume":"38","author":"Marks DJ","year":"2010","unstructured":"Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010, 38:20-31. 10.1007\/s12016-009-8133-2","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000527452","article-title":"Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis","volume":"104","author":"Mikami Y","year":"2023","unstructured":"Mikami Y, Tsunoda J, Suzuki S, Mizushima I, Kiyohara H, Kanai T. Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis. Digestion. 2023, 104:58-65. 10.1159\/000527452","journal-title":"Digestion"},{"key":"ref12","article-title":"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease","author":"Cheifetz A","year":"2024","unstructured":"Cheifetz A, Cullen G. Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease. UpToDate. Post T (ed): UpToDate, Waltham, MA; 2024."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691480","article-title":"Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice","volume":"12","author":"Bruscoli S","year":"2021","unstructured":"Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Front Immunol. 2021, 12:691480. 10.3389\/fimmu.2021.691480","journal-title":"Front Immunol"},{"key":"ref14","article-title":"Sulfasalazine","author":"Choi J","year":"2024","unstructured":"Choi J, Patel P, Fenando A. Sulfasalazine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221078456","article-title":"A review of the therapeutic management of Crohn's disease","volume":"15","author":"Kumar A","year":"2022","unstructured":"Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn's disease. Therap Adv Gastroenterol. 2022, 15:17562848221078456. 10.1177\/17562848221078456","journal-title":"Therap Adv Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8351","article-title":"Medical management of Crohn's disease","volume":"12","author":"Gade AK","year":"2020","unstructured":"Gade AK, Douthit NT, Townsley E. Medical management of Crohn's disease. Cureus. 2020, 12:e8351. 10.7759\/cureus.8351","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X699341","article-title":"Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care","volume":"68","author":"Barrett K","year":"2018","unstructured":"Barrett K, Saxena S, Pollok R. Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care. Br J Gen Pract. 2018, 68:497-8. 10.3399\/bjgp18X699341","journal-title":"Br J Gen Pract"},{"key":"ref18","article-title":"Corticosteroids","author":"Hodgens A","year":"2023","unstructured":"Hodgens A, Sharman T. Corticosteroids. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15576462","article-title":"From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease","volume":"8","author":"Randall CW","year":"2015","unstructured":"Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol. 2015, 8:143-59. 10.1177\/1756283X15576462","journal-title":"Therap Adv Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082244","article-title":"Anti-TNF therapy in Crohn's disease","volume":"19","author":"Adegbola SO","year":"2018","unstructured":"Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn's disease. Int J Mol Sci. 2018, 19:10.3390\/ijms19082244","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012893","article-title":"Certolizumab pegol for induction of remission in Crohn's disease","volume":"2017","author":"Yamazaki H","year":"2017","unstructured":"Yamazaki H, So R, Matsuoka K, et al.. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2017, 2017:CD012893. 10.1002\/14651858.CD012893","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319899297","article-title":"Emerging treatments for inflammatory bowel disease","volume":"11","author":"Hazel K","year":"2020","unstructured":"Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020, 11:2040622319899297. 10.1177\/2040622319899297","journal-title":"Ther Adv Chronic Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1148137","article-title":"Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease","volume":"25","author":"McLean LP","year":"2016","unstructured":"McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. Expert Opin Investig Drugs. 2016, 25:263-73. 10.1517\/13543784.2016.1148137","journal-title":"Expert Opin Investig Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.1078","article-title":"Role of antibiotics for treatment of inflammatory bowel disease","volume":"22","author":"Nitzan O","year":"2016","unstructured":"Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016, 22:1078-87. 10.3748\/wjg.v22.i3.1078","journal-title":"World J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i5.648","article-title":"Use of antibiotics in the treatment of Crohn's disease","volume":"19","author":"Scribano ML","year":"2013","unstructured":"Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn's disease. World J Gastroenterol. 2013, 19:648-53. 10.3748\/wjg.v19.i5.648","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214990","article-title":"A practical guide to therapeutic drug monitoring of biologic medications for inflammatory bowel disease","volume":"10","author":"Vaughn BP","year":"2021","unstructured":"Vaughn BP. A practical guide to therapeutic drug monitoring of biologic medications for inflammatory bowel disease. J Clin Med. 2021, 10:10.3390\/jcm10214990","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S379446","article-title":"Clinical evaluation of risankizumab in the treatment of adults with moderately to severely active Crohn's disease: patient selection and reported outcomes","volume":"17","author":"Horst S","year":"2023","unstructured":"Horst S, Cross RK. Clinical evaluation of risankizumab in the treatment of adults with moderately to severely active Crohn's disease: patient selection and reported outcomes. Drug Des Devel Ther. 2023, 17:273-82. 10.2147\/DDDT.S379446","journal-title":"Drug Des Devel Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50657","article-title":"Upadacitinib in Crohn's disease: a comprehensive systematic review of efficacy and safety","volume":"15","author":"Wodeyar AM","year":"2023","unstructured":"Wodeyar AM, Pansuriya N, Saeed S, et al.. Upadacitinib in Crohn's disease: a comprehensive systematic review of efficacy and safety. Cureus. 2023, 15:e50657. 10.7759\/cureus.50657","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820931738","article-title":"Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?","volume":"13","author":"Quaresma AB","year":"2020","unstructured":"Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?. Therap Adv Gastroenterol. 2020, 13:1756284820931738. 10.1177\/1756284820931738","journal-title":"Therap Adv Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel JF","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al.. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017, 66:839-51. 10.1136\/gutjnl-2015-311079","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"29","author":"Feagan BG","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D'Haens G, et al.. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017, 29:1699-709. 10.1016\/S0140-6736(17)30570-6","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2295496","article-title":"Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data","volume":"17","author":"Johnson A","year":"2023","unstructured":"Johnson A, Loftus E Jr. Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data. Expert Rev Gastroenterol Hepatol. 2023, 17:1169-83. 10.1080\/17474124.2023.2295496","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02878-8","article-title":"Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian randomization study","volume":"21","author":"Xu S","year":"2023","unstructured":"Xu S, Li X, Zhang S, et al.. Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian randomization study. BMC Med. 2023, 21:179. 10.1186\/s12916-023-02878-8","journal-title":"BMC Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02477-2","article-title":"Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn's disease","volume":"40","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Griffith J, Neimark E, et al.. Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn's disease. Adv Ther. 2023, 40:2311-25. 10.1007\/s12325-023-02477-2","journal-title":"Adv Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.008","article-title":"Clinical bridging from prefilled syringe to on-body injector for risankizumab in Crohn's disease","volume":"46","author":"Pang Y","year":"2024","unstructured":"Pang Y, D'Cunha R, Mohammad AS, et al.. Clinical bridging from prefilled syringe to on-body injector for risankizumab in Crohn's disease. Clin Ther. 2024, 46:30-9. 10.1016\/j.clinthera.2023.10.008","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao X","year":"2024","unstructured":"Gao X, Fujii T, Ye BD, et al.. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Gastroenterol Hepatol. 2024, 39:55-65. 10.1111\/jgh.16358","journal-title":"J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad168","article-title":"Maintenance risankizumab sustains induction response in patients with Crohn's disease in a randomized phase 3 trial","volume":"18","author":"Ferrante M","year":"2024","unstructured":"Ferrante M, Irving PM, Abreu MT, et al.. Maintenance risankizumab sustains induction response in patients with Crohn's disease in a randomized phase 3 trial. J Crohns Colitis. 2024, 18:416-23. 10.1093\/ecco-jcc\/jjad168","journal-title":"J Crohns Colitis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath MF","year":"2014","unstructured":"Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014, 14:329-42. 10.1038\/nri3661","journal-title":"Nat Rev Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, et al.. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology. 2020, 158:2123-2138.e8. 10.1053\/j.gastro.2020.01.047","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of Janus kinase 1 inhibition with upadacitinib in the Crohn's disease intestinal mucosa: analysis from the CELEST study","volume":"27","author":"Aguilar D","year":"2021","unstructured":"Aguilar D, Revilla L, Garrido-Trigo A, et al.. Randomized controlled trial substudy of cell-specific mechanisms of Janus kinase 1 inhibition with upadacitinib in the Crohn's disease intestinal mucosa: analysis from the CELEST study. Inflamm Bowel Dis. 2021, 27:1999-2009. 10.1093\/ibd\/izab116","journal-title":"Inflamm Bowel Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn's disease","volume":"19","author":"Chugh R","year":"2023","unstructured":"Chugh R, Braga-Neto MB, Fredrick TW, et al.. Multicentre real-world experience of upadacitinib in the treatment of Crohn's disease. J Crohns Colitis. 2023, 19:504-512. 10.1093\/ecco-jcc\/jjac157","journal-title":"J Crohns Colitis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2023.22515","article-title":"Epigenetics of inflammatory bowel diseases","volume":"34","author":"T\u00f6r\u00fcner M","year":"2023","unstructured":"T\u00f6r\u00fcner M, \u00dcnal NG. Epigenetics of inflammatory bowel diseases. Turk J Gastroenterol. 2023, 34:437-48. 10.5152\/tjg.2023.22515","journal-title":"Turk J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn's disease","volume":"69","author":"Miyatani Y","year":"2024","unstructured":"Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn's disease. Dig Dis Sci. 2024, 69:355-9. 10.1007\/s10620-023-08182-y","journal-title":"Dig Dis Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al.. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023, 388:1966-80. 10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38277","article-title":"Comparison of effectiveness and safety of ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease: a systematic review and meta-analysis","volume":"15","author":"Chenna VS","year":"2023","unstructured":"Chenna VS, Nagi TK, Suarez ZK, et al.. Comparison of effectiveness and safety of ustekinumab and adalimumab as induction or maintenance therapy in patients with moderate to severe Crohn's disease: a systematic review and meta-analysis. Cureus. 2023, 15:e38277. 10.7759\/cureus.38277","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01916-2","article-title":"Anti-TNF agents and new biological agents (vedolizumab and ustekinumab) in the prevention and treatment of postoperative recurrence after surgery in Crohn's disease","volume":"83","author":"Gisbert JP","year":"2023","unstructured":"Gisbert JP, Chaparro M. Anti-TNF agents and new biological agents (vedolizumab and ustekinumab) in the prevention and treatment of postoperative recurrence after surgery in Crohn's disease. Drugs. 2023, 83:1179-205. 10.1007\/s40265-023-01916-2","journal-title":"Drugs"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi TL","year":"2022","unstructured":"Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: what is in the pipeline?. J Crohns Colitis. 2022, 16:ii64-72. 10.1093\/ecco-jcc\/jjab185","journal-title":"J Crohns Colitis"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2022.00029","article-title":"Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease","volume":"21","author":"Koh SJ","year":"2023","unstructured":"Koh SJ, Hong SN, Park SK, et al.. Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. Intest Res. 2023, 21:43-60. 10.5217\/ir.2022.00029","journal-title":"Intest Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48338","article-title":"Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review","volume":"15","author":"Ashraf H","year":"2023","unstructured":"Ashraf H, Bodapati A, Hanif A, Okafor DK, Katyal G, Kaur G, Khan S. Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review. Cureus. 2023, 15:e48338. 10.7759\/cureus.48338","journal-title":"Cureus"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144202","article-title":"Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of Crohn's disease: systematic review and meta-analysis of observational studies","volume":"11","author":"Rub\u00edn de C\u00e9lix C","year":"2022","unstructured":"Rub\u00edn de C\u00e9lix C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of Crohn's disease: systematic review and meta-analysis of observational studies. J Clin Med. 2022, 11:10.3390\/jcm11144202","journal-title":"J Clin Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100081","article-title":"Managing complex perianal disease after anti-TNF failure: where to go next?","volume":"3","author":"Yzet C","year":"2022","unstructured":"Yzet C, Brazier F, Sabbagh C, Fumery M. Managing complex perianal disease after anti-TNF failure: where to go next?. Curr Res Pharmacol Drug Discov. 2022, 3:100081. 10.1016\/j.crphar.2022.100081","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100089","article-title":"Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises","volume":"3","author":"Alsoud D","year":"2022","unstructured":"Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises. Curr Res Pharmacol Drug Discov. 2022, 3:100089. 10.1016\/j.crphar.2022.100089","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.023","article-title":"AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Singh S","year":"2021","unstructured":"Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021, 160:2512-2556.e9. 10.1053\/j.gastro.2021.04.023","journal-title":"Gastroenterology"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121748","article-title":"Pharmacogenetics of biological agents used in inflammatory bowel disease: a systematic review","volume":"9","author":"Lauro R","year":"2021","unstructured":"Lauro R, Mannino F, Irrera N, et al.. Pharmacogenetics of biological agents used in inflammatory bowel disease: a systematic review. Biomedicines. 2021, 9:10.3390\/biomedicines9121748","journal-title":"Biomedicines"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: practical issues","volume":"10","author":"Tamilarasan AG","year":"2019","unstructured":"Tamilarasan AG, Cunningham G, Irving PM, Samaan MA. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol. 2019, 10:409-16. 10.1136\/flgastro-2018-101054","journal-title":"Frontline Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack RJ","year":"2022","unstructured":"Slack RJ, Macdonald SJ, Roper JA, Jenkins RG, Hatley RJ. Emerging therapeutic opportunities for integrin inhibitors. Nat Rev Drug Discov. 2022, 21:60-78. 10.1038\/s41573-021-00284-4","journal-title":"Nat Rev Drug Discov"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1159\/000527340","article-title":"Current status and future prospects of inflammatory bowel disease genetics","volume":"104","author":"Kakuta Y","year":"2023","unstructured":"Kakuta Y, Naito T, Kinouchi Y, Masamune A. Current status and future prospects of inflammatory bowel disease genetics. Digestion. 2023, 104:7-15. 10.1159\/000527340","journal-title":"Digestion"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162521","article-title":"Cell cycle regulation by integrin-mediated adhesion","volume":"11","author":"Kamranvar SA","year":"2022","unstructured":"Kamranvar SA, Rani B, Johansson S. Cell cycle regulation by integrin-mediated adhesion. Cells. 2022, 11:10.3390\/cells11162521","journal-title":"Cells"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2018.08.004","article-title":"Signal transduction via integrin adhesion complexes","volume":"56","author":"Humphries JD","year":"2019","unstructured":"Humphries JD, Chastney MR, Askari JA, Humphries MJ. Signal transduction via integrin adhesion complexes. Curr Opin Cell Biol. 2019, 56:14-21. 10.1016\/j.ceb.2018.08.004","journal-title":"Curr Opin Cell Biol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112996","article-title":"IL-2 can signal via chemokine receptors to promote regulatory T\u00a0cells' suppressive function","volume":"42","author":"Sun H","year":"2023","unstructured":"Sun H, Lee HS, Kim SH, et al.. IL-2 can signal via chemokine receptors to promote regulatory T\u00a0cells' suppressive function. Cell Rep. 2023, 42:112996. 10.1016\/j.celrep.2023.112996","journal-title":"Cell Rep"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221098899","article-title":"Vedolizumab blocks \u03b14\u03b27 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis","volume":"15","author":"Besendorf L","year":"2022","unstructured":"Besendorf L, M\u00fcller TM, Geppert CI, et al.. Vedolizumab blocks \u03b14\u03b27 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therap Adv Gastroenterol. 2022, 15:17562848221098899. 10.1177\/17562848221098899","journal-title":"Therap Adv Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01264-4","article-title":"Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities","volume":"21","author":"Li S","year":"2023","unstructured":"Li S, Sampson C, Liu C, Piao HL, Liu HX. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell Commun Signal. 2023, 21:266. 10.1186\/s12964-023-01264-4","journal-title":"Cell Commun Signal"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.038","article-title":"Integrins and their role in immune cell adhesion","volume":"177","author":"Dustin ML","year":"2019","unstructured":"Dustin ML. Integrins and their role in immune cell adhesion. Cell. 2019, 177:499-501. 10.1016\/j.cell.2019.03.038","journal-title":"Cell"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0316-9","article-title":"Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease","volume":"55","author":"Coskun M","year":"2016","unstructured":"Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016, 55:257-74. 10.1007\/s40262-015-0316-9","journal-title":"Clin Pharmacokinet"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16892","article-title":"Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease","volume":"56","author":"Vaughan R","year":"2022","unstructured":"Vaughan R, Tjandra D, Patwardhan A, et al.. Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther. 2022, 56:84-94. 10.1111\/apt.16892","journal-title":"Aliment Pharmacol Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.10.012","article-title":"Cholinergic anti-inflammatory pathway attenuates acute liver failure through inhibiting MAdCAM1\/\u03b14\u03b27-mediated gut-derived proinflammatory lymphocytes accumulation","volume":"17","author":"Fu S","year":"2024","unstructured":"Fu S, Ni T, Zhang M, et al.. Cholinergic anti-inflammatory pathway attenuates acute liver failure through inhibiting MAdCAM1\/\u03b14\u03b27-mediated gut-derived proinflammatory lymphocytes accumulation. Cell Mol Gastroenterol Hepatol. 2024, 17:199-217. 10.1016\/j.jcmgh.2023.10.012","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis","volume":"21","author":"Chandar AK","year":"2015","unstructured":"Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV Jr. Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2015, 21:1695-708. 10.1097\/MIB.0000000000000373","journal-title":"Inflamm Bowel Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy077","article-title":"Soluble mucosal addressin cell adhesion molecule 1 and retinoic acid are potential tools for therapeutic drug monitoring in patients with inflammatory bowel disease treated with vedolizumab: a proof of concept study","volume":"12","author":"Paul S","year":"2018","unstructured":"Paul S, Williet N, Di Bernado T, et al.. Soluble mucosal addressin cell adhesion molecule 1 and retinoic acid are potential tools for therapeutic drug monitoring in patients with inflammatory bowel disease treated with vedolizumab: a proof of concept study. J Crohns Colitis. 2018, 12:1089-96. 10.1093\/ecco-jcc\/jjy077","journal-title":"J Crohns Colitis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy307","article-title":"Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis","volume":"25","author":"Battat R","year":"2019","unstructured":"Battat R, Dulai PS, Vande Casteele N, et al.. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis. Inflamm Bowel Dis. 2019, 25:410-20. 10.1093\/ibd\/izy307","journal-title":"Inflamm Bowel Dis"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","volume":"71-72","author":"Liu J","year":"2023","unstructured":"Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023, 71-72:1-12. 10.1016\/j.cytogfr.2023.07.001","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/244415-advancements-in-targeted-therapies-for-the-management-of-crohns-disease-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T23:17:20Z","timestamp":1717629440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/244415-advancements-in-targeted-therapies-for-the-management-of-crohns-disease-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.61751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}